Nurix Therapeutics Inc Aktie News

Nurix Therapeutics is positioned for a breakthrough in CLL with NX-5948, demonstrating strong efficacy in post-Pirtobrutinib settings. Phase 1 data showed an 83% response rate at 600mg and 22.1 months of progression-free survival, enabling direct advancement to phase 3 trials. NRIX holds $680M in cash, supporting R&D through 2027-2028 and minimizing dilution risk for shareholders.

Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nurix Therapeutics offers a compelling risk/reward profile, driven by bexobrutideg's superior efficacy in B-cell malignancies versus current therapies. NRIX's strong cash position—over $650 million—funds operations through 2028, supporting aggressive R&D and pivotal trial advancement. Bexobrutideg's unique BTK degradation mechanism delivers longer progression-free survival and CNS activity, add...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T.

Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript

Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-free survival (PFS) have not been reached Encouraging efficacy and favorable tolerability support continued development of bexobrutideg in Waldenströ...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested